# Dr. Reddy's Laboratories

Source: https://onco.cc/companies/dr-reddys/  
OnCo record `dr-reddys` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Hyderabad generics maker that launched the world's first rituximab biosimilar in 2007 and now sells oncology generics and biosimilars in India, the US and Europe.

## Summary

Dr. Reddy's was founded in 1984 by Kallam Anji Reddy and is listed on the NSE, BSE and NYSE. It was an early mover in biosimilars: its rituximab, Reditux, was approved in India in 2007, the first rituximab biosimilar anywhere, and its EU rituximab (Ituxredi) was authorised in September 2024 at a price several times below the reference brand. The company is a major supplier of oncology generics (abiraterone, bortezomib, azacitidine, decitabine and many injectables) to the US and India, and its oncology-focused subsidiary Aurigene runs discovery and clinical programmes. Dr. Reddy's also in-licenses innovative oncology products for India.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Hyderabad
- Type: pharma
- Website: https://www.drreddys.com
- Ticker: RDY

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Dr._Reddy's_Laboratories
- Official website: https://www.drreddys.com

## Connected records

- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Biosimilar manufacturing and comparability](https://onco.cc/technologies/biosimilar-manufacturing/), [Generic sterile injectables (the 2023 platinum shortage)](https://onco.cc/technologies/sterile-injectable-generics-manufacturing/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Oral solid dose manufacturing (tablets and capsules)](https://onco.cc/technologies/oral-solid-dose-manufacturing/), [Small-molecule API synthesis](https://onco.cc/technologies/small-molecule-api-synthesis/)
- targets: [CD20](https://onco.cc/targets/cd20/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Azacitidine](https://onco.cc/drugs/azacitidine/), [Bortezomib](https://onco.cc/drugs/bortezomib/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [Aurigene Oncology](https://onco.cc/companies/aurigene/)
- terms: [Biosimilar](https://onco.cc/terms/biosimilar/)
- bottlenecks: [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)
- roadmaps: [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/dr-reddys.json